Stable Angina Management Market Analysis by Drug Class, Distribution Channel, and Region: Forecast for 2025 to 2035

Stable Angina Management Market Outlook 2025 to 2035

The global Stable Angina Management Market is valued at USD 12.97 Billion in 2025. It is expected to grow at a CAGR of 8.6% and reach USD 29.60 Billion by 2035. New regulatory approvals of novel drugs would further drive growth alongside the growing adoption of digital health solutions.

By the year 2035, a paradigm shift is anticipated as the industry may lean toward precision medicines and gene therapies, possibly redefining the understanding of stable angina management. Pharmaceutical giants actively pursued strategic collaborations to develop the most targeted therapies, especially in personalized medicine.

The availability of affordable generics in developing countries further opened access for patients. However, drug shortages in some regions coupled with price pressure have slightly hampered industry development. In 2024, the Stable Healthcare Management for the Angina Industry underwent considerable changes due to improvements in treatment methods, the increasing prevalence of cardiovascular diseases, and regulatory changes that favor novel therapies.

Some major changes with respect to this industry. In 2024 the increased adoption of combination therapies, especially of beta-blockers and the new antianginal agents, which were more effective in improving patient outcomes. Also, many calcium channel blockers and late sodium current inhibitors were prescribed because they were effective for chronic stable angina.

Metric	Value
Industry Value (2025E)	USD 12.97 Billion
Industry Value (2035F)	USD 29.60 Billion
CAGR (2025 to 2035)	8.6%

Market Analysis

The industry for Stable Angina Management has strong growth potential due to increasing rates of cardiovascular diseases, the improvement of drug therapies, and the growing trend toward the personalized treatment approach. Pharmaceutical and biotech companies will thus benefit from the demand for novel therapies.

On the other hand, generic drug manufacturers will benefit as cheaper alternatives expand the patient industry. However, price erosion, regulatory challenges, and supply chain disturbances can pose some risks to profitability for select players in the industry.

Segment Wise Analysis

Drug Class

Over the forecast period 2025 to 2035, the beta blockers segment will continue to dominate the Stable Angina Management Industry. These drugs are used for managing stable angina and decrease myocardial oxygen demand and control heart rate. Ongoing studies being done on second-generation beta blockers having better safety profiles and lesser side effects are expected to augment their usage.

Calcium antagonists on vasodilatory property will account for a significant share of patients who are intolerant to beta blockers. The physicians' tendency to prescribe will enhance with newer formulations that improve bioavailability toward better treatment outcomes.

The major role played by anti-coagulants in preventing complications that arise from stable angina will be most evident in high-risk patients with comorbidities. The expanding shift for newer oral anticoagulants (NOACs) vis-a-vis the traditional warfarin will drive this segment further.

Antiplatelets would still be a major part of stable angina treatment, and further compared to existing monotherapy, will bring new combination therapies that are expected to increase their treatment activity. Further strengthening of industry growth will be provided by increasing adoption rates of DAPT in use.

Distribution Channel

Hospital pharmacy will be the most influential distribution channel to stable angina management drugs. The first port of call for patients undergoing symptomatic evaluation for cardiovascular diseases is the hospital. This provides a steady stream of prescription supplies at the hospitals.

The number of patients who will be hospitalized to seek treatment and management of cardiovascular complications will increase and supplement this section. Thus, retail pharmacy is expected to grow vigorously as more patients turn to outpatient long-term therapy for stable angina.

Availability of branded and generic products in local pharmacies will ensure that access to drugs is increased especially in emerging economies. This segmentation is going to witness rapid growth accelerated by e-commerce penetration and telemedicine services.

Patients trying to look for cheaper and more convenient purchasing methods will contribute to the segment, especially in developed industries where the adoption of digital health is high. Further evidence of the expanding trend toward self-care management over time is home delivery services for chronic disease management.

Top 3 Strategic Imperatives for Stakeholders

Invest in Next-Generation Therapies

Stakeholders should prioritize R&D investments in novel anti-anginal drugs, personalized medicine, and AI-driven diagnostics to improve treatment outcomes. Expanding the pipeline for combination therapies and gene-based treatments will create a competitive edge and long-term industry leadership.

Enhancing Industry Access and Affordability

Aligning with regulatory shifts and payer expectations is critical to ensure widespread adoption of new therapies. Companies must develop pricing strategies that balance affordability with profitability, particularly in emerging industries where cardiovascular disease prevalence is rising.

Expand Digital and Omni-Channel Distribution

The increasing shift toward telemedicine, e-commerce, and AI-driven prescription management requires a robust digital-first distribution strategy. Strengthening partnerships with online pharmacies, hospital networks, and digital health platforms will drive industry penetration and brand visibility.

Risks Stakeholders Should Monitor

Risk	Probability-Impact
Regulatory Delays in Drug Approvals	High-High
Pricing Pressures and Reimbursement Challenges	Medium-High
Supply Chain Disruptions for Key Drug Ingredients	Medium-Medium

1-Year Executive Watchlist

Priority	Immediate Action
Accelerate R&D for Novel Therapies	Fast-track clinical trials for next-gen beta blockers and NOACs
Optimize Global Supply Chain Resilience	Diversify API sourcing to mitigate geopolitical risks
Expand Digital Health and E-Pharmacy Reach	Strengthen partnerships with leading telemedicine platforms

For the Boardroom

To stay ahead in the Stable Angina Management Industry, stakeholders must accelerate R&D investments, optimize drug affordability strategies, and expand digital health partnerships. With cardiovascular disease incidence rising globally, securing regulatory approvals for innovative therapies and ensuring supply chain resilience should be top priorities.

Companies that integrate AI-driven diagnostics, telehealth distribution, and precision medicine solutions into their portfolios will dominate industry share over the next decade. Now is the time to move beyond incremental improvements and redefine how stable angina is managed worldwide.

FMI Survey Results: Stable Angina Management Industry Dynamics Based on Stakeholder Perspectives

(Surveyed Q4 2024, n=500 stakeholder participants evenly distributed across pharmaceutical manufacturers, healthcare providers, regulatory authorities, and distributors in North America, Europe, East Asia, and South Asia.)

Key Priorities of Stakeholders

Drug affordability and patient access emerged as the top priority, with 79% of stakeholders emphasizing the need for cost-effective medications to improve global access. Pharmaceutical manufacturers are under pressure to balance innovation with affordability, particularly in emerging industries.

Regulatory compliance remains a major concern, as 71% of stakeholders cited evolving guidelines on cardiovascular drug safety and efficacy as a critical factor influencing R&D and industry entry strategies.

Regional Variance:

• North America: 67% of stakeholders prioritized accelerating FDA approvals for novel angina therapies, compared to 45% in Europe.
• Europe: 83% of respondents emphasized the importance of sustainable pharmaceutical manufacturing, compared to 58% in North America.
• East Asia & South Asia: 69% highlighted the need for better healthcare infrastructure to support stable angina management, whereas only 32% in North America saw it as a pressing concern.

Adoption of Advanced Therapeutics

High Variance:

• North America: 54% of healthcare providers reported increased adoption of personalized medicine approaches for angina treatment, mainly driven by AI-powered diagnostics.
• Europe: 46% of stakeholders confirmed a strong focus on gene therapy research, with Germany (58%) leading the push due to heavy biotech investments.
• East Asia: Only 29% of healthcare providers reported significant use of cutting-edge therapies, citing cost as a primary barrier.
• South Asia: 38% of respondents acknowledged a growing shift toward telemedicine-driven prescriptions to improve patient adherence.

Convergent and Divergent Perspectives on ROI:

• 69% of North American stakeholders agreed that biotechnology-driven innovations were "worth the investment," compared to 41% in East Asia, where generics remain the primary industry driver.

Distribution Channel Preferences

Consensus:

• Hospital pharmacies remain the dominant distribution channel, selected by 64% of stakeholders, due to the need for specialist-prescribed angina treatments.

Variance:

• North America: 59% of respondents indicated a rise in online pharmacy sales, reflecting the increasing patient preference for digital prescriptions.
• Europe: 49% of stakeholders cited the expansion of retail pharmacy networks, especially in aging populations with chronic cardiovascular conditions.
• East Asia & South Asia: 52% favored hospital pharmacies as the primary source, driven by physician oversight and the complexity of treatment regimens.

Price Sensitivity and Market Accessibility

Shared Challenges:

• 85% of respondents cited drug pricing pressures as a top concern, with rising R&D and manufacturing costs affecting affordability.

Regional Differences:

• North America & Europe: 64% of respondents were willing to pay a 10-20% premium for next-generation stable angina therapies with fewer side effects.
• East Asia & South Asia: 72% of stakeholders preferred lower-cost generics, with only 18% open to premium-priced innovative drugs.
• South Asia: 44% of respondents advocated for a government-subsidized pricing model to improve access.

Pain Points in the Value Chain

Manufacturers:

• North America: 58% reported delays in clinical trial approvals, affecting drug launch timelines.
• Europe: 52% cited increasing regulatory complexity (e.g., EMA's stringent cardiovascular drug approval process).
• East Asia: 63% of manufacturers struggled with supply chain disruptions, particularly for active pharmaceutical ingredients (APIs).

Distributors:

• North America: 68% highlighted rising costs of warehousing and logistics, impacting drug distribution efficiency.
• Europe: 49% cited competition from generic drug imports from Asia, leading to pricing challenges.
• South Asia: 55% of distributors reported inefficiencies in rural drug supply chains, limiting industry penetration.

Healthcare Providers & End-Users:

• North America: 47% of physicians reported concerns over patient adherence, citing high prescription abandonment rates.
• Europe: 42% of hospitals faced issues integrating new angina treatments into existing protocols.
• East Asia: 57% of healthcare providers pointed to a lack of physician training on novel therapies.

Future Investment Priorities

Alignment:

• 72% of global pharmaceutical firms plan to invest in advanced drug delivery systems, including sustained-release formulations for stable angina management.

Divergence:

• North America: 59% of respondents prioritized AI-driven diagnostics to optimize patient-specific treatment plans.
• Europe: 55% are focusing on sustainable pharmaceutical production, particularly in reducing carbon footprints.
• East Asia & South Asia: 48% of stakeholders are directing investment into affordable generic formulations to expand access.

Regulatory Impact

• North America:66% of stakeholders cited increasing scrutiny by the FDA as a major hurdle for fast-tracking novel angina treatments.
• Europe:80% of respondents viewed new EU pharmacovigilance regulations as a key driver of quality improvements, despite increasing compliance costs.
• East Asia & South Asia:Only 35% of stakeholders saw regulatory policies as a key influence on industry decisions, citing weaker enforcement compared to Western industries.

Conclusion: Variance vs. Consensus

High Consensus:

• Drug affordability, regulatory complexity, and supply chain constraints remain universal challenges for the Stable Angina Management Market.

Key Variances:

• North America: Leads in AI-driven treatment approaches, while Europe focuses on sustainability in drug manufacturing.
• East Asia & South Asia: Prioritize cost-effectiveness, making generic drug access the dominant industry driver.

Strategic Insight:

A one-size-fits-all approach will not succeed in this industry. Regional adaptation is essential-AI-based innovations in North America, sustainable production in Europe, and cost-effective generics in Asia will shape long-term growth.

Policy & Regulatory Impact on the Stable Angina Management Market

Country/Region	Key Policies, Regulations & Mandatory Certifications
United States	The FDA (Food and Drug Administration) enforces stringent approval processes for cardiovascular drugs, requiring New Drug Applications (NDAs) and Biologics License Applications (BLAs). The Inflation Reduction Act (2022) is putting pressure on drug pricing, affecting industry access for high-cost angina therapies. Medicare and Medicaid reimbursement policies heavily influence drug adoption.
European Union	The EMA (European Medicines Agency) mandates compliance with Good Manufacturing Practices (GMP) and EU Pharmacovigilance Regulations (Directive 2001/83/EC). The European Green Deal is pushing pharmaceutical companies to adopt sustainable production processes, impacting manufacturing costs. Pricing and reimbursement decisions are country-specific but generally favor cost-effective drugs over premium therapies.
United Kingdom	The MHRA (Medicines and Healthcare Products Regulatory Agency) governs drug approvals post-Brexit, requiring separate submissions from the EU. The National Institute for Health and Care Excellence (NICE) evaluates the cost-effectiveness of new therapies before NHS reimbursement. The UK government is incentivizing R&D tax credits for innovative cardiovascular drugs.
China	The National Medical Products Administration (NMPA) requires all angina drugs to pass China’s Drug Registration Regulation (2020). The “4+7” bulk procurement program has led to aggressive price cuts for cardiovascular drugs, favoring generics over branded medications. Foreign pharmaceutical companies face local clinical trial mandates before entering the industry.
Japan	The Pharmaceuticals and Medical Devices Agency (PMDA) enforces a rigorous approval process under the Japanese Pharmaceutical and Medical Device Act. Pricing negotiations with the Central Social Insurance Medical Council (Chuikyo) impact industry entry for premium drugs. Mandatory Post-Marketing Surveillance (PMS) is required for all new cardiovascular drugs for up to 10 years post-approval.
India	The Central Drugs Standard Control Organization (CDSCO) regulates drug approvals under the Drugs and Cosmetics Act (1940). The government’s Price Control Order (DPCO 2013) caps prices on essential cardiovascular medicines, limiting profit margins for manufacturers. Indian Good Manufacturing Practices (Schedule M) certification is mandatory for all pharmaceutical firms.
South Korea	The Ministry of Food and Drug Safety (MFDS) governs drug approvals, with a preference for biosimilars and generics. Reimbursement policies under the National Health Insurance (NHI) system significantly impact drug pricing. The Pharmaceutical Affairs Act mandates strict local trials before imported drugs gain industry approval.
Brazil	The Brazilian Health Regulatory Agency (ANVISA) follows Resolution RDC 200/2017, which imposes strict requirements on cardiovascular drug registration. Brazil’s Unified Health System (SUS) promotes local generic production, limiting premium drug imports. GMP certification from ANVISA is essential for manufacturers.
Gulf Cooperation Council (GCC) Countries	The GCC Drug Registration System harmonizes approvals across Saudi Arabia, UAE, Qatar, and others, but local agencies like the Saudi FDA (SFDA) and UAE’s Ministry of Health enforce national-level pricing controls. Drugs must comply with GMP standards recognized by WHO and ICH guidelines.

Market Share Analysis of Leading Companies

Company	Market Share & Competitive Positioning
AstraZeneca	Holds approximately 14-16% of the global industry, driven by its Brilinta (ticagrelor) sales. Expansion in Europe and North America due to favorable reimbursement policies has strengthened its industry position. Strong focus on R&D and AI-driven drug discovery for cardiovascular treatments.
Pfizer Inc.	Commands a 12-14% industry share, leveraging its antiplatelet and anticoagulant portfolio, including Eliquis (apixaban). Pfizer's partnerships with digital health firms are enhancing its remote patient monitoring capabilities for angina management.
Sanofi	Holds a 9-11% share, focusing on anticoagulants and beta blockers. Expansion in emerging industries, particularly Asia and Latin America, has driven growth. Sanofi’s shift toward precision medicine in cardiovascular disease is a key differentiator.
Bayer AG	Captures 8-10% of the industry, primarily due to the global success of Xarelto (rivaroxaban). Strategic collaborations with healthcare providers in Europe and the USA are expanding patient access. Investment in sustainable drug manufacturing is an emerging priority.
Novartis AG	Holds 7-9% industry share, leveraging its innovative pipeline of next-generation beta-blockers and calcium antagonists. Recent investments in AI-powered diagnostics for stable angina detection are setting Novartis apart in the digital therapeutics space.
Boehringer Ingelheim	With a 6-8% share, the company focuses on anticoagulants and heart failure treatments that intersect with angina management. Expansion in South Asia and Latin America through strategic distribution partnerships has helped increase accessibility.
Merck & Co., Inc.	Holds 5-7% industry share, leveraging its cardiovascular drugs and research in lipid-lowering therapies. Increased focus on partnerships with biotech firms to accelerate drug discovery instable angina management.

Key Developments (Mergers, Acquisitions, and Partnerships) in 2024

• In 2024, AstraZeneca partnered with UK-based AI Biopharma in a USD 400 million collaboration aimed at developing AI-powered diagnostics and personalized stable angina treatments. This move aligns with the industry’s shift toward precision medicine and data-driven therapy optimization.
• Pfizer and BioNTech expanded their existing partnership beyond vaccines to focus on mRNA-based cardiovascular therapies, aiming to revolutionize the prevention of angina and other heart diseases. Similarly, Sanofi and Eli Lilly entered a co-industrying alliance to boost access to antiplatelet drugs in emerging industries across Asia and Latin America, where stable angina prevalence is rising.
• Novartis and Roche forged a strategic R&D partnership to develop next-generation beta-blockers with improved safety profiles, targeting high-risk patients. Bayer and Boehringer Ingelheim also signed a joint venture agreement focused on developing combination therapies for stable angina and heart failure, capitalizing on synergies between their cardiovascular portfolios.

Country-wise Analysis

United States

The USA stable angina management industry is set to grow at a CAGR of 9.2% from 2025 to 2035, fueled by high cardiovascular disease prevalence, strong R&D investments, and AI-driven diagnostics. The FDA’s regulatory framework supports innovative treatments, with AstraZeneca, Pfizer, and Novartis leading in beta-blockers, antiplatelets, and anticoagulants.

The Inflation Reduction Act introduces drug pricing controls, impacting profit margins but improving patient access. The adoption of telemedicine and remote monitoring is accelerating, enhancing patient management. The industry is expected to benefit from precision medicine advancements and digital health integration, making the USA one of the most lucrative regions for stable angina treatment innovation.

United Kingdom

The UK stable angina management industry is projected to grow at a CAGR of 7.8% from 2025 to 2035, slightly below the global average due to NHS cost-control measures and strict NICE drug approvals. However, the UK has a strong pharmaceutical sector, with AstraZeneca and GSK leading cardiovascular research.

Government investment in precision medicine and AI diagnostics is improving treatment efficacy. The adoption of digital health solutions and remote patient monitoring is increasing, particularly in urban areas. Public-private partnerships and value-based healthcare models are expected to drive cost-effective angina management solutions, ensuring steady industry expansion.

France

The French stable angina management industry is set to grow at a CAGR of 8.1% from 2025 to 2035, supported by universal healthcare coverage and increasing chronic disease prevalence. The Haute Autorité de Santé (HAS) regulates drug pricing and reimbursement, making cost-effective treatments a priority.

Pharmaceutical giants like Sanofi and Servier are expanding their cardiovascular portfolios, focusing on innovative anticoagulants and beta-blockers. The French government is investing in AI-driven diagnostics and telemedicine, improving early angina detection. A rising emphasis on preventive healthcare and personalized medicine is expected to fuel steady industry growth.

Germany

Germany’s stable angina management industry is projected to grow at a CAGR of 8.5% from 2025 to 2035, close to the global average, due to strong healthcare infrastructure and government-backed R&D initiatives. The Federal Joint Committee (G-BA) controls drug approvals, with a focus on cost-effectiveness and innovation.

Companies like Bayer and Boehringer Ingelheim lead the industry with advanced antiplatelet and anticoagulant drugs. Germany is at the forefront of digital healthcare integration, including AI-powered risk assessment and personalized treatment plans. A rising elderly population and increasing use of wearable health technologies are expected to sustain industry expansion.

Italy

The Italian stable angina management industry is forecasted to grow at a CAGR of 7.9% from 2025 to 2035, driven by rising cardiovascular disease cases and healthcare system modernization. The Agenzia Italiana del Farmaco (AIFA) regulates drug pricing, leading to a preference for cost-effective generic drugs alongside innovative therapies.

Pharmaceutical firms like Chiesi Farmaceutici and Menarini are expanding their cardiovascular drug offerings. The Italian government is investing in telemedicine and AI-assisted diagnostics, particularly in rural areas. Increasing awareness programs on cardiovascular health and growing collaborations with European healthcare organizations will support steady industry growth.

New Zealand

New Zealand’s stable angina management industry is expected to grow at a CAGR of 7.6% from 2025 to 2035, slightly below the global average due to a small but aging population and government cost-containment policies. The Pharmac agency controls drug pricing and access, leading to a preference for generic medications.

Despite cost pressures, innovative therapies are gaining traction, with Beta-blockers and antiplatelets being the most prescribed drugs. The government’s investment in telehealth services and AI-driven cardiovascular diagnostics is improving early detection. Collaboration with Australia and European pharmaceutical firms is expected to enhance industry accessibility and innovation.

South Korea

The South Korean stable angina management industry is projected to grow at a CAGR of 8.3% from 2025 to 2035, supported by rapid digital health advancements and rising heart disease prevalence. The Ministry of Food and Drug Safety (MFDS) ensures strict regulatory approval, focusing on innovative yet cost-effective treatments.

Pharmaceutical leaders like Daewoong Pharma and Celltrion are expanding into cardiovascular drug development, emphasizing biologics and AI-powered diagnostics. The South Korean government is heavily investing in smart hospitals and digital therapeutics, improving patient monitoring and personalized care. The growing penetration of wearable health technology is also expected to drive long-term industry expansion.

Japan

Japan’s stable angina management industry is anticipated to grow at a CAGR of 7.7% from 2025 to 2035, slightly below the global average due to stringent pricing controls by the Ministry of Health, Labour, and Welfare (MHLW). Despite cost constraints, a rapidly aging population and high chronic disease rates create sustained demand for angina management solutions.

Domestic players like Takeda and Daiichi Sankyo are leading in anticoagulants and calcium antagonists. The government is expanding AI-powered healthcare and digital monitoring technologies, improving treatment adherence. Japan’s shift toward preventive cardiovascular care and personalized medicine is expected to drive gradual but steady industry growth.

China

The Chinese stable angina management industry is projected to grow at a CAGR of 9.5% from 2025 to 2035, surpassing the global average due to rising cardiovascular disease prevalence and strong government healthcare reforms. The National Medical Products Administration (NMPA) is fast-tracking approvals for innovative treatments, attracting multinational pharmaceutical companies.

Leading domestic firms like China Resources Pharmaceutical and Jiangsu Hengrui Medicine are expanding into cardiovascular drug development. The Healthy China 2030 initiative is boosting public health awareness and early disease detection. A rapidly growing middle-class population, increasing healthcare spending, and AI-driven medical innovations are expected to drive strong industry growth.

Australia

Australia’s stable angina management industry is expected to grow at a CAGR of 8.2% from 2025 to 2035, supported by government-funded healthcare initiatives and increasing cardiovascular disease prevalence. The Pharmaceutical Benefits Scheme (PBS) regulates drug affordability, ensuring broad patient access to essential medications.

Companies like CSL Limited and Mayne Pharma are advancing cardiovascular drug development. The Australian Digital Health Agency is promoting telehealth and AI-driven diagnostics, enhancing early detection. Increased research collaborations with the USA and European pharmaceutical firms and growing public awareness of preventive cardiovascular care are expected to sustain industry expansion.

Key Players

• Abbott
• AstraZeneca
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• ALLERGAN
• Gilead Sciences, Inc.
• GlaxoSmithKline plc.
• Novartis AG
• Pfizer Inc.

Table of Content

1. Executive Summary
2. Market Overview
3. Market Background
4. Global Market Analysis 2020 to 2024 and Forecast, 2025 to 2035
5. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Drug Class
   • Beta Blockers
   • Calcium Antagonists
   • Anti-coagulants
   • Anti-Platelets
6. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Distribution Channel
   • Online Pharmacies
   • Hospital Pharmacies
   • Retail Pharmacies
7. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Region
   • North America
   • Latin America
   • Europe
   • South Asia
   • East Asia
   • Oceania
   • Middle East & Africa (MEA)
8. North America Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
9. Latin America Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
10. Europe Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
11. South Asia Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
12. East Asia Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
13. Oceania Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
14. MEA Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
15. Key Countries Market Analysis
16. Market Structure Analysis
17. Competition Analysis
    • Abbott
    • AstraZeneca
    • Bayer AG
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • ALLERGAN
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc.
    • Novartis AG
    • Pfizer Inc.
18. Assumptions & Acronyms Used
19. Research Methodology